Abacavir/Lamivudine + Ledipasvir/Sofosbuvir = Unknown or no reaction

Effect on Concentration

Abacavir/Lamivudine
No change
Applies within class?
No
Ledipasvir/Sofosbuvir
No change
Applies within class?
No

Pharmacologic Effects

Abacavir/Lamivudine
Effect
N/A
Applies within class?
No
Ledipasvir/Sofosbuvir
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 18-Jul-2018

Summary

Sources

Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. ^

Study Design

The drug-drug interaction potential of ledipasvir/sofosbuvir (LDV/SOF) with abacavir/lamivudine (ABC/3TC) was assessed in a pharmacokinetic evaluation. LDV/SOF was administered as 90/400mg QD and ABC/3TC as 600/300mg QD.

Study Results

No effect on the PK parameters of LDV, SOF (or circulating metabolite GS-331007), ABC or 3TC was observed when LDV/SOF was co-administered with ABC/3TC. The magnitude of change in the pharmacokinetic parameters was not stated.

Study Conclusions

The authors state that LDV/SOF may be co-administered with ABC/3TC.

References

German P, Pang P, West S, Han L, Sajwani K, Matias A. Drug interactions between direct acting anti-hcv antivirals sofosbuvir and ledipasvir and hiv antiretrovirals. International Workshop On Clinical Pharmacology Of Hiv And Hepatitis Therapy . Washingston DC, USA. 15; May 2014.